SRR13311171
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.650
- MYC_TARGETS_V1+0.610
- OXIDATIVE_PHOSPHORYLATION+0.600
- DNA_REPAIR+0.410
- PEROXISOME+0.400
- MTORC1_SIGNALING+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- ADIPOGENESIS+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.330
- FATTY_ACID_METABOLISM+0.290
Top 10 suppressed
- NOTCH_SIGNALING-0.350
- APICAL_SURFACE-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- INFLAMMATORY_RESPONSE-0.250
- HEDGEHOG_SIGNALING-0.240
- KRAS_SIGNALING_UP-0.240
- UV_RESPONSE_DN-0.230
- TGF_BETA_SIGNALING-0.220
- IL6_JAK_STAT3_SIGNALING-0.210
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-AA5N-01A-11R-A42T-07 | — | — | 0.855 |
| 2 | C3N-01024 | — | cohortA1 | 0.849 |
| 3 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.832 |
| 4 | SRR23036894 | — | — | 0.831 |
| 5 | MNG709 | — | — | 0.831 |
| 6 | SRR1313126 | — | C | 0.825 |
| 7 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.821 |
| 8 | 652298ba-554a-4fad-9d8b-aceaee37f9f2 | — | — | 0.818 |
| 9 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.818 |
| 10 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.650 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.610 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| PEROXISOME | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |